Belinda Juran's practice focuses on advising clients on technology-centered transactions. She helps biotechnology, pharmaceutical, medical device, high technology and service companies achieve their strategic goals by advising them on all phases of their product development and commercialization relationships. Ms. Juran negotiates and advises clients on collaboration, development, distribution, license and service agreements with customers, suppliers, licensors, licensees and other third parties, and on the acquisition and sale of intellectual property and joint venture arrangements. She works with clients on matters ranging from bet-the-company billion-dollar global strategic collaborations to day-to-day issues. Ms. Juran also has provided general corporate advice to public and private companies and has represented companies in venture capital financings, initial public offerings and mergers and acquisitions. She also works closely with WilmerHale's IP litigation team, negotiating settlement and license agreements to settle ANDA and other litigation matters.
Ms. Juran provides her clients with practical insights by combining her experience and education in technology, business and law. Prior to practicing law, Ms. Juran worked in the high technology industry for several years, where she developed sophisticated computer-aided engineering software, then managed engineering departments. She has also been a consultant to several high technology companies.
Learn more about Ms. Juran's practice and how she can support your startup on WilmerHaleLaunch.com.
Ms. Juran sits on the board of directors of UTEC, the United Teen Equality Center of Lowell, Massachusetts. Through job training, education and social support, UTEC enables Lowell's most disconnected young people to trade violence and poverty for social and economic success.
Ms. Juran has participated in the M. Ellen Carpenter Financial Literacy Program conducted through the Boston Bar Association.
- Has represented Infinity Pharmaceuticals in its significant collaborations, including Infinity’s broad drug discovery collaboration with Purdue and the restructuring of that relationship, and Infinity’s collaboration with Intellikine on PI3K and the restructuring of that relationship
- Has represented Idenix Pharmaceuticals in its significant collaborations, including, most recently, the reversion of development-stage rights to Idenix through the restructuring of its almost decade-long relationship with Novartis, on which Ms. Juran has advised from its inception
- Has represented Constellation Pharmaceuticals in several transactions, including its collaboration and option agreements with Genentech and its funding collaboration with The Leukemia & Lymphoma Society® for BET inhibitor
- Has represented Synta Pharmaceuticals in several development and commercialization collaboration, including with Hoffman-La Roche for drugs to treat inflammatory diseases
- Has represented The Medicines Company in several development and commercialization collaborations, including its acquisition of Recothrom® assets from Bristol Myers Squibb and their related collaboration
- Represented Enobia Pharma in the negotiation of the earn-out provisions in its acquisition by Alexion Pharmaceuticals, which may entitle Enobia’s stockholders to up to $470 million in milestone payments in addition to the $610 million paid up-front in cash
- Has represented Aciex Therapeutics in several transactions, including an ophthalmic collaboration with Portola Pharmaceuticals
- Represented Montreal-based Bellus Health in several transactions, including the acquisition of rights to eprodisate by Celtic Therapeutics
- Has represented Millennium Pharmaceuticals in several license and collaboration agreements
- Has represented Cerulean Pharma in several drug development and licensing agreements
- Represented Visterra in an antibody discovery collaboration with Pfizer
- Represented Rhythmia Medical in several transactions, including the negotiation of earn-outs in its acquisition by Boston Scientific
- Represented Cubist Pharmaceuticals in a license and supply agreement with Teva to settle ANDA litigation
- Represented Durata Therapeutics in the acquisition of RaQualia’s Japanese rights to dalbavancin, a MRSA compound
- Represented Somaxon Pharmaceuticals in settlement and licensing agreements to settle ANDA litigation
- Selected by peers for inclusion in the 2018 edition of the Best Lawyers in America for her biotechnology law practice
- Recommended in the 2016 and 2017 editions of The Legal 500 United States for her work in M&A/Corporate and Commercial; Media, Technology and Telecoms: Outsourcing and Transactions; and Healthcare: Life Sciences
- Named a Life Sciences Star in the 2016-2017 editions of LMG Life Sciences for finance and transactional
- Recognized by The Legal 500 United States in 2013 as "a fantastic collaborator" and "outstanding in licensing"
- LMG Life Sciences selected the firm as winner of its “Canadian Impact Deals of the Year” in 2013 award for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.
- Named to the Women's Business Boston's Top 10 Corporate Lawyers list
Insights & News
JD, Harvard Law School, 1998cum laude
MBA, Boston University, 1995magna cum laude
BS, Mathematics, University of Scranton, 1981summa cum laude